Translation and validation into Brazilian Portuguese of the Spastic Paraplegia Rating Scale (SPRS)

ABSTRACT

Hereditary spastic paraplegias (HSP) are characterized by progressive lower limb weakness and spasticity. There are no validated instruments to quantify disease severity in Portuguese.

Objective To translate and validate the Spastic Paraplegia Rating Scale (SPRS) into Brazilian-Portuguese.

Method Two experienced and English-fluent neurologists translated SPRS into Portuguese, creating SPRS-BR. We then assessed inter and intra-rater reliability of this version using coefficients of correlation and variability in a cohort of 30 patients.

Results Mean age of patients and disease duration were 47.7 ± 10.5 and 17.0 ± 10.6 years, respectively. Twenty-one had pure HSP and SPG4 was the most frequent genotype. Mean Rankin and SPRS-BR scores were 2.2 ± 0.9 and 19.9 ± 9.9, respectively. Mean intra and inter-rater correlation coefficients of SPRS-BR scores were 0.951 and 0.934, whereas coefficients of variation were 11.5% (inter-rater) and 9.9% (intra-rater). Cronbach’s alpha for the whole SPRS-BR scale was 0.873.

Conclusion SPRS-BR is a useful, reliable and valid clinical instrument.

RESUMO

As paraparesias espásticas hereditárias (PEH) apresentam progressiva espasticidade e fraqueza dos membros inferiores. Não existem escalas validadas em língua portuguesa para quantificar a gravidade da doença.

Objetivo Traduzir e validar para o português do Brasil a Spastic Paraplegia Rating Scale (SPRS).

Método Dois neurologistas experientes em neurogenética e fluentes em inglês traduziram a SPRS para o português, criando a SPRS-BR. Em seguida, checamos a reprodutibilidade da escala usando coeficientes de correlação e variabilidade em um grupo de 30 pacientes.

Resultados As médias de idade e duração de doença foram de 47,7 ± 10,5 e 17,0 ± 10,6 anos, respectivamente. Vinte e um eram portadores da forma pura de PEH, sendo que SPG4 foi o genótipo mais frequente. A pontuação das escalas Rankin e SPRS-BR foi, respectivamente, 2,2 ± 0,9 e 19,9 ± 9,9. Os coeficientes de correlação inter e intraexaminador da SPRS-BR foram 0,934 e 0,951, enquanto que os coeficientes de variação foram de 11,5% (interexaminador) e 9,9% (intraexaminador). O coeficiente alfa de Cronbach’s para a escala SPRS-BR foi de 0.873.

Conclusão A SPRS-BR é uma escala útil clinicamente, fácil de aplicar e que apresentou boa reprodutibilidade e validade.

spastic paraplegia - hereditary - scales - tranlating

paraplegia espástica hereditária - escalas - tradução

Publication History

Received: 04 December 2015

Accepted: 24 February 2016

Article published online:
06 September 2023

• References

• 1 Fink JK. Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms. Acta Neuropathol. 2013;126(3):307-28. doi:10.1007/s00401-013-1115-8
• 2 Reid E. Pure hereditary spastic paraplegia. J Med Genet. 1997;34(6):499-503. doi:10.1136/jmg.34.6.499
• 3 Klimpe S, Schüle R, Kassubek J, Otto S, Kohl Z, Klebe S et al. Disease severity affects quality of life of hereditary spastic paraplegia patients. Eur J Neurol. 2012;19(1):168-171. doi:10.1111/j.1468-1331.2011.03443.x
• 4 Faber I, Servelhere KR, Martinez ARM, D’Abreu A, Lopes-Cendes I, França MC Jr. Clinical features and management of hereditary spastic paraplegia. Arq Neuropsiquiatr. 2014;72(3):219-26. doi:10.1590/0004-282X20130248
• 5 Lo Giudice T, Lombardi F, Santorelli FM, Kawarai T, Orlacchio A. Hereditary spastic paraplegia: clinical-genetic characteristics and evolving molecular mechanisms. Exp Neurol. 2014;261:518-39. doi:10.1016/j.expneurol.2014.06.011
• 6 Schüle R, Holland-Letz T, Klimpe S, Kassubek J, Klopstock T, Mall V et al. The Spastic Paraplegia Rating Scale: a reliable and valid measure of disease severity. Neurology. 2006;67(3):430-4. doi:10.1212/01.wnl.0000228242.53336
• 7 Béreau M, Anheim M, Chanson JB, Tio G, Echaniz-Laguna A, Depienne C et al. Dalfampridine in hereditary spastic paraplegia: a prospective open study. J Neurol. 2015;262(5):1285-8. doi:10.1007/s00415-015-7707-6
• 8 Lindig T, Bender B, Hauser TK, Mang S, Schweikardt D, Klose U et al. Gray and white matter alterations in hereditary spastic paraplegia type SPG4 and clinical correlations. J Neurol. 2015;262(8):1961-71. doi:10.1007/s00415-015-7791-7
• 9 Orsucci D, Petrucci L, Ienco EC, Chico L, Simi P, Fogli A et al. Hereditary spastic paraparesis in adults: a clinical and genetic perspective from Tuscany. Clin Neurol Neurosurg. 2014;120:14-9. doi:10.1016/j.clineuro.2014.02.002
• 10 Rezende TJ, Albuquerque M, Lamas GM, Martinez AR, Campos BM, Casseb RF et al. Multimodal MRI-based study in patients with SPG4 mutations. PLoS One. 2015;10(2):e0117666. doi:10.1371/journal.pone.0117666
• 11 Wilson JT, Hareendran A, Grant M, Baird T, Schulz UG, Muir KW et al. Improving the Assessment of outcomes in stroke: use of a structured interview to assign grades on the modified rankin scale. Stroke. 2002;33(9):2243-6. doi:10.1161/01.STR.0000027437.22450.BD
• 12 Tavares IR, Franzoi AC, Araújo AQ-C. Low-back pain in HTLV-I-associated myelopathy/tropical spastic paraparesis: nociceptive or neuropathic? Spinal Cord. 2010;48(2):134-7. doi:10.1038/sc.2009.83
• 13 Castro-Costa CM, Araújo AQ, Câmara CC, Ferreira AS, Santos TJ, Castro-Costa SB et al. Pain in tropical spastic paraparesis/HTLV-I associated myelopathy patients. Arq Neuropsiquiatr. 2009;67(3B):866-70. doi:10.1590/S0004-282X2009000500016